ZIM Laboratories Limited announced that INFARMED (Portugal) – The Portuguese National Authority of Medicines and Health Products has granted the Marketing Authorisation (MA) for one of ZIM’s New Innovative Products – Azithromycin for Oral Suspension 200 mg/5ml – in Portugal to ZIM’s wholly owned European Subsidiary – SIA ZIM Laboratories Limited.
This is the 1st Marketing Authorisation (MA) for ZIM for its New Innovative Products (NIP) for Europe. Azithromycin Oral Suspension is differentiated in taste masked suspension dosage form which benefits patients who have difficulty in swallowing and children who have difficulty with bitter taste.
According to IQVIA, the EU market size for this product in 2022 was approx. USD 300Mn. Additionally other target markets for ZIM such as SE Asia & Oceania, Latin America and MENA have a combined market size of approx. USD 900Mn